The Latest Breaking News from AstraZeneca

City Voices: Taken together, London’s top flight mightn’t look so appealing. But that doesn’t mean that all UK stocks should be written off.

The biotech industry’s growth prospects look promising due to advanced technologies like AI, the growing popularity of tailored treatments, a rise in chronic diseases, and higher R&D spending. Let's analyze the investment prospects of biotech stocks Innoviva (INVA), Organogenesis Holdings (ORGO), and Compugen (CGEN). Read more.

Next-generation cancer therapies are here. AstraZeneca - already an oncology leader - is going down the path of radiopharmaceuticals with its purchase of Fusion. Along with the other potential blockbuster drugs in its pipeline, this should bode well for growth at AZN.

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

AstraZeneca said Tuesday is would acquire Fusion Pharmaceuticals for $2 billion upfront. The biotech stock nearly doubled.

Britain’s biggest drugmaker’s latest acquisition will help it to develop new radiotherapy treatments

Confronted by the huge salaries on offer in the US, London boardrooms are lobbying to be allowed to make their own bosses even wealthier

Hospitality trade says chancellor failed to help save sector with VAT cut, while travel industry laments air duty rise

While Novo Nordisk's Wegovy currently dominates the obesity treatment market, Morgan Stanley sees more upside potential for LLY and AZN stocks going forward.